<code id='DFE5532761'></code><style id='DFE5532761'></style>
      • <acronym id='DFE5532761'></acronym>
      <center id='DFE5532761'><center id='DFE5532761'><tfoot id='DFE5532761'></tfoot></center><abbr id='DFE5532761'><dir id='DFE5532761'><tfoot id='DFE5532761'></tfoot><noframes id='DFE5532761'>
      • <optgroup id='DFE5532761'><strike id='DFE5532761'><sup id='DFE5532761'></sup></strike><code id='DFE5532761'></code></optgroup>
        5. <b id='DFE5532761'><label id='DFE5532761'><select id='DFE5532761'><dt id='DFE5532761'><span id='DFE5532761'></span></dt></select></label></b><u id='DFE5532761'></u>
          <i id='DFE5532761'><strike id='DFE5532761'><tt id='DFE5532761'><pre id='DFE5532761'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / fashion / focus      
           
     
           
      
          focus 
           
      
           
      
           
       2025-09-27 22:50:21 
   
      
           
      
           
                        
          focus  
          
                                   
                 
                                      author：explore   
                                        
                                      
                                      Page View：39
                                  
                                    
          
                                   
          Stock exchange
          Drew Angerer/Getty Images
          Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development. 
          The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.
          advertisement
          In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Can we make enough H5N1 bird flu vaccine if there's a pandemic?
                                
                            
          Next article：  
                                      
                                          After affirmative action ruling, medical educators look to 'holistic review'
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles